- Poster presentation
- Open Access
Decreased expression of HLA-DR antigen-associated invariant chain mRNA predicts mortality after septic shock
© Cazalis et al.; licensee BioMed Central Ltd. 2012
- Published: 14 November 2012
- Septic Shock Patient
- Major Histocompatibility Class
- Multicentric Clinical Study
- CD74 mRNA Level
- Septic Syndrome
Septic syndromes remain the leading cause of mortality in ICUs. Patients rapidly develop immune dysfunctions of which intensity and duration have been linked with increased risk of secondary ICU-acquired infections and death. A decreased expression on circulating monocytes of human leukocyte-antigen DR (mHLA-DR) measured by flow cytometry has been shown to be a good marker of sepsis-induced immune dysfunctions  and to correlate with increased risk of death and ICU-acquired infections [2, 3]. However, pre-analytical and analytical issues inherent to mHLA-DR measurement by flow cytometry limit the use of this marker in large multicentric clinical studies and on a routine basis. We investigated whether the whole blood mRNA expression of genes related to major histocompatibility class II (MHC class II) antigens could correlate with mHLA-DR protein expression measured by flow cytometry and predict mortality in septic shock patients.
Ninety-three septic shock patients were included. PAXgene® tubes were collected at days 3 to 4 after the onset of shock. The mRNA expression of five MHC class II-related genes (that is, CD74, HLA-DRA, HLA-DMB, HLA-DMA and CIITA) was measured by qRT-PCR. In parallel, ethylene diamine tetraacetic acid-anticoagulated blood samples were collected to measure mHLA-DR expression by flow cytometry.
Decreased invariant chain mRNA expression significantly predicts 28-day mortality in septic shock patients. After validation in a larger multicentric study, this biomarker could become a robust predictor of mortality in septic patients. This is all the more because the availability in routine laboratories of molecular biology platforms will enable standardized and routine use of such biomarkers.
- Monneret G, Venet F, Pachot A, Lepape A: Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony. Mol Med 2008, 14: 64-78.PubMed CentralView ArticlePubMedGoogle Scholar
- Monneret G, Lepape A, Voirin N, Bohé J, Venet F, Debard AL, Thizy H, Bienvenu J, Gueyffier F, Vanhems P: Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med 2006, 32: 1175-1183. 10.1007/s00134-006-0204-8View ArticlePubMedGoogle Scholar
- Landelle C, Lepape A, Voirin N, Tognet E, Venet F, Bohé J, Vanhems P, Monneret G: Low monocyte human leukocyte antigen-DR is independently associated with nosocomial infections after septic shock. Intensive Care Med 2010, 36: 1859-1866. 10.1007/s00134-010-1962-xView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.